Curated News
By: NewsRamp Editorial Staff
October 13, 2026
VERAXA Biotech's BiTAC-ADC Shows Tumor Regression in First In Vivo Data
TLDR
- VERAXA Biotech's BiTAC-ADC platform showed tumor regression in breast cancer, offering a competitive edge in next-gen cancer therapies.
- BiTAC-ADC technology uses two components to target cancer cells specifically, sparing healthy cells and reducing systemic toxicity in preclinical studies.
- VERAXA Biotech's BiTAC-ADC platform aims to improve cancer treatment by reducing side effects and enhancing patient safety.
- BiTAC-ADC technology requires both components to work, ensuring tumor-specific response and potentially transforming cancer therapy.
Impact - Why it Matters
This news matters because it represents a potential leap forward in cancer treatment. Current antibody-drug conjugates (ADCs) often cause systemic toxicity due to payload release outside tumors, limiting their therapeutic window. VERAXA's BiTAC-ADC platform, with its dual-component design, appears to specifically activate only in the tumor microenvironment, potentially reducing side effects while maintaining efficacy. If these preclinical results translate to humans, patients could benefit from more tolerable and effective therapies for breast cancer and other malignancies. The successful in vivo proof-of-concept also validates VERAXA's innovative approach, attracting investor attention and accelerating the path to clinical trials. As the company advances its pipeline, it may contribute to a new generation of targeted cancer therapeutics that improve outcomes and quality of life.
Summary
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has unveiled promising preclinical data for its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. According to NEWMEDIAWIRE, the company presented its first in vivo proof-of-concept results, demonstrating significant tumor regression in a breast cancer model after a single 3 mg/kg dose, with no observed decrease in body weight. Notably, both components of the BiTAC-ADC were required to achieve the intended tumor-specific response, underscoring the platform's precision. Additional in vitro studies showed the technology's ability to distinguish cancer cells from healthy cells, prevent the release of active toxins outside the tumor, and target multiple cancer cell lines.
These findings support the potential of BiTAC-ADCs to deliver efficacy comparable to conventional antibody-drug conjugates while offering a differentiated safety profile designed to reduce systemic toxicity. VERAXA, founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH. For more details, the full press release is available at https://ibn.fm/cs8SW, and the latest updates relating to VRXA can be found in the company's newsroom at https://ibn.fm/VRXA. As with any forward-looking statements, risks and uncertainties apply.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, VERAXA Biotech's BiTAC-ADC Shows Tumor Regression in First In Vivo Data
